Search

Your search keyword '"Artusi, C.A."' showing total 2 results
Start Over Author "Artusi, C.A." Topic 0302 clinical medicine
2 results on '"Artusi, C.A."'

1. Should We Consider Deep Brain Stimulation Discontinuation in Late-Stage Parkinson's Disease?

Author

Tommaso Tufo, Margherita Fabbri, Romito Luigi, Linda Borellini, Nicola Modugno, Andrea Bruno, Elisa Montanaro, Leonardo Lopiano, Gianluca Ardolino, Filippo Cogiamanian, Paola Berchialla, Carlo Alberto Artusi, Maurizio Zibetti, Antonella Peppe, Carla Piano, Mario Giorgio Rizzone, Brigida Minafra, Claudio Pacchetti, Giulia Giannini, Alberto Romagnolo, Roberto Eleopra, Giovanna Calandra-Buonaura, Alessandro Stefani, Francesco Bove, Pietro Cortelli, Fabbri M., Zibetti M., Rizzone M.G., Giannini G., Borellini L., Stefani A., Bove F., Bruno A., Calandra Buonaura G., Modugno N., Piano C., Peppe A., Ardolino G., Romagnolo A., Artusi C.A., Berchialla P., Montanaro E., Cortelli P., Luigi R., Eleopra R., Minafra B., Pacchetti C., Tufo T., Cogiamanian F., and Lopiano L.

Subjects
0301 basic medicine, medicine.medical_specialty, caregivers, Parkinson's disease, Deep brain stimulation, medicine.medical_treatment, Deep Brain Stimulation, Stimulation, Settore MED/05, deep brain stimulation, dementia, late stage, Parkinson’s disease, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Subthalamic Nucleus, Internal medicine, medicine, Humans, Adverse effect, caregiver, business.industry, Parkinsonism, Parkinson Disease, medicine.disease, Dysphagia, nervous system diseases, Discontinuation, 030104 developmental biology, Treatment Outcome, Neurology, England, Neurology (clinical), medicine.symptom, business, 030217 neurology & neurosurgery
Abstract

Background: Subthalamic deep brain stimulation (STN-DBS) effects may decrease with Parkinson’s disease (PD) progression. There is no indication if, when, and how to consider the interruption of DBS treatment in late-stage PD. The objective of the current study was to investigate the percentage of “poor stimulation responders” among late-stage PD patients for elaborating an algorithm to decide whether and when DBS discontinuation may be considered. Methods: Late-stage PD patients (Hoehn Yahr stage ≥4 and Schwab and England Scale

Published
2020

2. Levodopa/Carbidopa Intestinal Gel Long-Term Outcome in Parkinson's Disease: Focus on Dyskinesia

Author

Manuela Contin, Luisa Sambati, Maurizio Zibetti, Susan Mohamed, Giovanna Calandra-Buonaura, Gabriele Imbalzano, Carlo Alberto Artusi, Pietro Cortelli, Giulia Giannini, Alberto Romagnolo, Leonardo Lopiano, Paola Berchialla, Margherita Fabbri, Mario Giorgio Rizzone, Fabbri M., Zibetti M., Calandra Buonaura G., Contin M., Sambati L., Mohamed S., Romagnolo A., Berchialla P., Imbalzano G., Giannini G., Rizzone M.G., Artusi C.A., Cortelli P., and Lopiano L.

Subjects
0301 basic medicine, Levodopa, medicine.medical_specialty, Parkinson's disease, 030105 genetics & heredity, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Female patient, medicine, otorhinolaryngologic diseases, gender, dyskinesia, levodopa/carbidopa intestinal gel, Research Articles, business.industry, Odds ratio, medicine.disease, Confidence interval, nervous system diseases, Neurology, Dyskinesia, Pharmacodynamics, Levodopa carbidopa, Neurology (clinical), medicine.symptom, business, 030217 neurology & neurosurgery, medicine.drug
Abstract

Background Levodopa-carbidopa intestinal gel (LCIG) treatment has shown variable effect on dyskinesia in Parkinson's disease (PD). Objective To identify PD patients who are likely to have troublesome dyskinesia under LCIG treatment and describe the pharmacokinetic-dynamic profile and dyskinesia phenomenology of those patients. Methods PD patients were assessed for clinical and therapeutic variables, before LCIG treatment (T0) and at last outpatient visit (T1). Sub-groups of patients with and without "troublesome dyskinesia" (UPDRS IV, item 33 ≥2), matched for disease and LCIG treatment duration, underwent a pharmacokinetic-dynamic assessment. Results We included 53 PD patients. After a mean of 51.7 ± 34.1 months of LCIG treatment, "off-time" was significantly reduced, whereas, dyskinesia duration/disability did not change. The multivariate regression model, adjusted for LCIG treatment duration, showed that being female increases the risk of presenting troublesome dyskinesia at T1 (odds ratio [OR] = 9.2; 95% confidence interval [CI] = 2.4-37.4) that was also significantly associated to longer off periods at T1 (OR= 4.4; 95% CI = 1.1-14.3). Female patients showed a higher risk for a higher dyskinesia score at T1 (sum of the items 32 and 33: P = 0.001). Patients with troublesome dyskinesia showed a tendency for a lower motor benefit and the appearance of more severe dyskinesia despite similar levodopa plasma concentration. Conclusion Dyskinesia should be carefully monitored in patients undergoing LCIG, with particular caution for female patients. Whether combined clinical and pharmacodynamic assessments could be helpful to manage patients with troublesome dyskinesia under LCIG treatment needs further evaluation in a larger group of patients.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results